Bluebird Bio, Inc. (BLUE): David Davidson , Chief Medical Officer of Bluebird Bio, Inc. sold 1,000 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $38.73 per share for a total value of $38,729.30 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 19, 2016, David Davidson (Chief Medical Officer) sold 1,000 shares at $49.63 per share price.On Dec 9, 2015, Nick Leschly (CEO) purchased 9,682 shares at $51.75 per share price.Also, On Dec 4, 2015, Eric Sullivan (Principal Accounting Officer) sold 416 shares at $81.13 per share price.On Nov 12, 2015, Jeffrey T. Walsh (Chief Operating Officer) sold 11,000 shares at $74.60 per share price.
Shares of bluebird bio Inc (BLUE) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.56 points or -1.42% at $38.83 with 5,62,322 shares getting traded. Post opening the session at $39.16, the shares hit an intraday low of $38.18 and an intraday high of $40.43 and the price vacillated in this range throughout the day. The company has a market cap of $1,434 M and the number of outstanding shares has been calculated to be 3,69,43,048 shares. The 52-week high of bluebird bio Inc is $197.35 and the 52-week low is $35.37.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.